AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes US Affiliate AM-Pharma Inc.
17 September 2021 - - Netherlands-based pharmaceutical company AM-Pharma B.V has appointed Lars R. Boesgaard as chief financial officer, effective immediately, the company said.

Boesgaard's career spans 25 years and includes CFO roles at public and private companies, where he built experience with Initial Public offering transactions, capital markets and product commercialization in the healthcare industry with both large pharmaceutical and biotechnology companies.

He has specialized in preparing and executing corporate transactions and building financial frameworks for rapidly growing organizations.

Boesgaard will be AM-Pharma's first US-based executive team member, and will play an integral role as the company builds a broader global footprint to prepare for the potential US commercialization of ilofotase alfa, currently in Phase III clinical development.

Prior to joining AM-Pharma, Lars Boesgaard was CFO of Columbia Care, based in New York City, where he completed key transactions including an IPO/reverse merger resulting in USD 120m capital infusion and raising a further USD 200m in public equity and debt offerings.

Before that, he served as CFO of NASDAQ-listed Roka Bioscience, based in Warren, New Jersey, where he directed IPO preparations and led investor relations.

Before Roka, he held several senior finance positions with US-NASDAQ-listed companies Insulet Corp. and Alexion Pharmaceuticals as well as Denmark-based Novo Nordisk A/S.

He holds a BSc in Business Administration from the Copenhagen Business School and an MBA from the Richard Ivey School of Business, Western University, Ontario, Canada.

AM-Pharma's initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year.

The company said its proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial.